Human BCMA x E. coli β-Gal Bispecific Antibody - Negative Control

Monoclonal scFv antibody against human BCMA and β-galactosidase - Negative control

Anti-hBCMA-βGal is a bispecific antibody that binds to two sites: human B cell maturation antigen (hBCMA) and E. coli β-galactosidase (β-Gal). It is used as a negative control for Anti-hBCMA-CD3 bispecific antibody that, like pacanalotamab, engages unstimulated T cells to proliferate and exert cytotoxic activity on BCMA-positive myeloma cells [1].

The human BCMA (also known as CD269 or TNFRSF17) plays a central role in B cell maturation and differentiation towards plasma cells [2]. It is expressed on plasma cells, mature B cells as well as multiple myeloma cells. By interacting with its ligands, hBCMA activates several pathways promoting B cell survival and proliferation but also tumor cell growth and drug resistance [2-3].

Key features

• Reacts with human BCMA
• Unable to interact with human CD3
• ScFv of clinical relevant bispecific mAb pacanalotamab
• Hexahistidine (His6) tag
• Provided azide-free
• Each lot is functionally tested

References:

1. Topp et al., 2020. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775-783.
2. Hosny et al., 2021. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J Clin Med. Oct 6;10(19):4593.
3. Abramson et al., 2020. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci. 2020;21(15):5192.